Evangelos Terpos

Evangelos Terpos's AcademicInfluence.com Rankings

Evangelos Terpos

Computer Science

#4141

World Rank

#4357

Historical Rank

Machine Learning

#722

World Rank

#732

Historical Rank

Artificial Intelligence

#926

World Rank

#943

Historical Rank

Database

#1373

World Rank

#1445

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Evangelos Terpos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Evangelos Terpos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
Hematological findings and complications of COVID‐19 (2020) (1325)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005) (871)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma (2009) (434)
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. (2009) (406)
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. (2003) (400)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (378)
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (2010) (373)
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. (2010) (365)
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. (2006) (352)
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). (2011) (328)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. (2017) (320)
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients (2006) (310)
Organ-specific manifestations of COVID-19 infection (2020) (309)
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. (2013) (309)
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications (2015) (283)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (279)
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. (2018) (263)
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. (2007) (245)
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid (2008) (243)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2016) (235)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. (2009) (235)
Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012) (229)
Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma (2006) (221)
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (2013) (216)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia (2004) (192)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014) (191)
Pathogenesis of bone disease in multiple myeloma: from bench to bedside (2018) (191)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) (2009) (190)
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group (2016) (189)
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone (2007) (184)
International Myeloma Working Group recommendations for global myeloma care (2014) (183)
Emerging treatment strategies for COVID-19 infection (2020) (179)
Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review (2013) (173)
Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma (2003) (167)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (156)
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy (2012) (155)
BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES. (2020) (153)
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel (2018) (152)
Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation (2006) (146)
Aurora kinases as targets for cancer therapy. (2008) (143)
Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease (2004) (142)
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease (2013) (140)
Natural history of osteonecrosis of the jaw in patients with multiple myeloma. (2008) (140)
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications (2021) (138)
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma (2013) (138)
Myeloma bone disease and proteasome inhibition therapies. (2007) (137)
Widespread occurrence of the JAK 2 V 617 F mutation in chronic myeloproliferative disorders (2005) (132)
Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. (2013) (129)
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. (2014) (127)
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2 (2012) (126)
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. (2012) (126)
Bone resorption is increased in young adults with thalassaemia major (2001) (125)
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine (2021) (123)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies (2010) (122)
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network (2014) (120)
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2 (2012) (118)
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. (2008) (116)
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group (2017) (112)
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents (2010) (110)
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. (2012) (109)
Sotatercept in patients with osteolytic lesions of multiple myeloma (2014) (109)
Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia (2003) (108)
Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients (2002) (108)
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. (2009) (107)
Advances in imaging and the management of myeloma bone disease. (2011) (106)
The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma (2014) (105)
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose (2021) (105)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives (2017) (104)
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. (2012) (103)
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide (2012) (100)
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) (2020) (98)
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. (2010) (97)
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio (2005) (97)
Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined significance (MGUS) (2004) (96)
Proteasome dysfunction in Drosophila signals to an Nrf2‐dependent regulatory circuit aiming to restore proteostasis and prevent premature aging (2013) (96)
Regulation of multiple myeloma survival and progression by CD1d. (2008) (95)
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. (2015) (95)
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients (2021) (93)
Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma (2003) (92)
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up (2021) (91)
Myeloma bone disease: pathophysiology and management. (2005) (91)
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma (2007) (90)
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment (2021) (90)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. (2021) (90)
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease (2010) (88)
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton (2007) (88)
Consensus on the utility of bone markers in the malignant bone disease setting. (2011) (87)
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. (2012) (86)
Cardiac and renal complications of carfilzomib in patients with multiple myeloma. (2017) (85)
Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study (2003) (84)
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens (2008) (83)
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. (2008) (83)
Prognostic evaluation of the microvascular network in myelodysplastic syndromes (2001) (81)
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018) (80)
Myeloma bone disease: from biology findings to treatment approaches. (2019) (80)
Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. (2011) (80)
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients (2012) (79)
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group (2010) (79)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review (2021) (77)
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma (2011) (77)
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. (2009) (76)
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when (2018) (75)
Increased bone resorption is implicated in the pathogenesis of bone loss in hemophiliacs: correlations with hemophilic arthropathy and HIV infection (2009) (75)
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) (2018) (75)
The potential of proteasome inhibitors in cancer therapy. (2008) (74)
Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma (2000) (73)
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. (2006) (73)
Significance of macrophage inflammatory protein-1 alpha (MIP-1α) in multiple myeloma (2005) (72)
Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. (2017) (72)
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. (2003) (72)
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. (2006) (71)
Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis (2016) (71)
Sickle‐cell disease and the heart: review of the current literature (2012) (71)
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (2008) (70)
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
Dickkopf-1: a suitable target for the management of myeloma bone disease (2009) (69)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma (2015) (69)
High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. (2008) (69)
Treatment options for thalassemia patients with osteoporosis (2010) (67)
Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myeloma (2005) (67)
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration (2009) (66)
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment (2010) (66)
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. (2019) (66)
Prevalence and significance of vitamin D deficiency in multiple myeloma patients (2008) (65)
Early markers of renal dysfunction in patients with sickle cell/β-thalassemia (2006) (65)
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. (2007) (64)
Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. (2007) (63)
The potential of proteasome inhibitors in cancer therapy (2008) (63)
Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents (2013) (62)
Activin receptor antagonists for cancer-related anemia and bone disease (2013) (61)
Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents (2010) (60)
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin‐6 and β2‐microglobulin in multiple myeloma (2003) (60)
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (2008) (58)
New insights into the pathophysiology and management of bone disease in multiple myeloma (2003) (58)
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration (2008) (58)
High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density (2012) (58)
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. (2019) (58)
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) (2018) (58)
The effect of teriparatide on serum Dickkopf‐1 levels in postmenopausal women with established osteoporosis (2009) (57)
Mechanisms of bone destruction in multiple myeloma (2017) (57)
Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group (2014) (57)
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. (2010) (57)
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. (2021) (56)
Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease (2014) (53)
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). (2009) (53)
The effects of bortezomib on bone disease in patients with multiple myeloma (2014) (53)
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma (2014) (53)
Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. (2006) (52)
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. (2016) (52)
Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. (2018) (51)
Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies (2015) (51)
Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma (2009) (51)
Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
Current treatments for renal failure due to multiple myeloma (2013) (50)
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration (2004) (50)
Management of bone disease in multiple myeloma (2014) (49)
Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis (2014) (49)
Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: Implications for multiple myeloma (2011) (48)
Impact of bortezomib on bone health in myeloma: a review of current evidence. (2012) (48)
The role of markers of bone remodeling in multiple myeloma. (2005) (48)
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single‐agent chelation therapies (2011) (48)
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group (2018) (48)
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women — The six-month effect of risedronate and teriparatide (2011) (47)
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. (2006) (47)
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial (2016) (47)
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors (2021) (46)
Biology and treatment of myeloma related bone disease. (2017) (46)
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients (2014) (46)
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial (2010) (45)
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (45)
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy (2017) (45)
Pathogenesis and management of myeloma bone disease (2009) (44)
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IκB kinase (2009) (44)
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience (2015) (43)
Pathogenesis and management of osteoporosis in thalassemia. (2008) (43)
Novel anti-myeloma agents and angiogenesis (2008) (43)
Optimal use of bisphosphonates in patients with multiple myeloma. (2013) (43)
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients (2021) (42)
CCL3 Signaling in the Tumor Microenvironment. (2020) (42)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
Multiple myeloma. (2010) (42)
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty (2010) (41)
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy (2015) (41)
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. (2018) (41)
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity (2009) (41)
The Emerging Role of Convalescent Plasma in the Treatment of COVID-19 (2020) (41)
Biochemical markers of bone metabolism in multiple myeloma. (2006) (41)
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? (2008) (41)
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. (2011) (41)
Bone health in the elderly cancer patient: A SIOG position paper. (2016) (40)
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma (2011) (40)
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens (2013) (40)
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis (2022) (40)
Clinical implications of chromosomal abnormalities in multiple myeloma (2006) (39)
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. (2011) (39)
Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (39)
Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. (2006) (38)
Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study (2020) (38)
“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group (2013) (38)
Role of the RANK/RANKL Pathway in Multiple Myeloma (2018) (38)
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis (2018) (38)
The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD‐EPI‐CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD‐EPI‐CysC equations? (2013) (38)
Multiple myeloma: Role of autologous transplantation. (2019) (38)
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19 (2020) (37)
PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy (2016) (37)
Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma (2017) (37)
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study (2021) (37)
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension (2019) (37)
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study (2021) (36)
Sjögren's syndrome associated with multiple myeloma (2000) (36)
Treatment with deferasirox (Exjade®) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study (2010) (35)
Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. (2001) (35)
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin‐1 to angiopoietin‐2 and angiogenin correlate with disease severity (2007) (35)
Systemic lupus erythematosus presenting as myelofibrosis. (1998) (35)
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma (2006) (35)
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. (2016) (34)
Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma (2008) (34)
Clinical vertebral fractures following denosumab discontinuation (2016) (34)
Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents (2012) (34)
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials (2013) (34)
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. (2010) (33)
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers (2021) (33)
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies (2018) (33)
The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. (2009) (32)
RANKL inhibition for the management of patients with benign metabolic bone disorders (2009) (32)
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group (2018) (32)
Deferiprone as an oral iron chelator in sickle cell disease (2005) (32)
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools (2020) (32)
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group (2014) (32)
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents (2014) (32)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens (2011) (31)
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib (2008) (31)
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma (2007) (31)
Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT (2014) (31)
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors (2021) (31)
Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis (2016) (31)
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies (2017) (30)
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. (2019) (30)
Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome (2012) (30)
Efficacy of Panobinostat for the Treatment of Multiple Myeloma (2020) (30)
Cost of skeletal complications from bone metastases in six European countries (2016) (30)
Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria. (2003) (30)
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point (2015) (30)
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib (2016) (30)
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit (2017) (30)
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years (2011) (29)
Renal insufficiency and failure. (2010) (29)
Sclerostin: a possible target for the management of cancer-induced bone disease (2012) (29)
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report (2020) (29)
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. (2013) (29)
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma (2013) (29)
Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era (2012) (29)
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma (2021) (29)
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial (2008) (29)
Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients (2010) (28)
Bisphosphonate treatment for multiple myeloma. (2004) (28)
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life (2021) (28)
Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. (2011) (28)
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. (2011) (28)
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine (2021) (28)
Clinical characteristics of patients with relapsed multiple myeloma. (2015) (28)
A revised international prognostic score system for Waldenström’s macroglobulinemia (2019) (28)
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. (2007) (27)
Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. (2009) (27)
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events (2017) (27)
Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications (2011) (27)
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens (2017) (27)
Pregnancy in beta‐thalassemia intermedia: 20‐year experience of a Greek thalassemia center (2014) (27)
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. (2016) (27)
Detection of CD55- and/or CD59-Deficient Red Cell Populations in Patients With Plasma Cell Dyscrasias (2002) (27)
Response to bortezomib of a patient with scleromyxedema refractory to other therapies. (2011) (27)
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches (2020) (27)
Management of complications in multiple myeloma. (2009) (27)
Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes. (2001) (27)
Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis (2005) (26)
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma (2021) (26)
Serum levels of total-RANKL in multiple myeloma. (2009) (26)
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection (2020) (26)
Emerging antibodies for the treatment of multiple myeloma (2016) (26)
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma (2018) (25)
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. (2007) (25)
Abnormal bone remodelling and increased levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) in Waldenström macroglobulinaemia (2006) (25)
Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection. (2008) (25)
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget’s disease (2010) (25)
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd (2020) (25)
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays (2021) (25)
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop (2019) (24)
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe (2018) (24)
How lenalidomide is changing the treatment of patients with multiple myeloma. (2013) (24)
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. (2010) (24)
Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β‐thalassemia major and severe iron burden (2014) (24)
Effects of proteasome inhibitors on bone cancer. (2013) (23)
Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study (2012) (23)
Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells. (2014) (22)
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals (2021) (22)
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis (2019) (22)
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma (2020) (22)
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease (2016) (22)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study) (2015) (22)
The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial. (2005) (21)
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events (2021) (21)
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. (2009) (21)
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. (2010) (21)
Tobacco smoking and risk of multiple myeloma: A meta‐analysis of 40 observational studies (2013) (21)
European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma (2021) (21)
Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients (2014) (21)
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study (2018) (21)
Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma (2005) (21)
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents (2015) (20)
Health resource utilization associated with skeletal-related events: results from a retrospective European study (2015) (20)
Osteoprotegerin to soluble receptor activator of nuclear factor κ‐B ligand ratio is reduced in patients with thalassaemia‐related osteoporosis who receive vitamin D3 (2005) (20)
Next generation flow cytometry for MRD detection in patients with AL amyloidosis (2020) (20)
Tumor‐primed natural killer cells from patients with multiple myeloma lyse autologous, NK‐resistant, bone marrow‐derived malignant plasma cells (2011) (20)
An overview of the role of carfilzomib in the treatment of multiple myeloma (2017) (20)
A review of the venous thrombotic issues associated with multiple myeloma (2016) (20)
Current treatments for renal failure due to multiple myeloma (2013) (19)
Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response (2009) (19)
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. (2019) (19)
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer (2009) (19)
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis (2017) (19)
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist (2021) (19)
Anti-BCMA antibodies in the future management of multiple myeloma (2019) (19)
Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: A case report and review of the literature (2001) (18)
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma (2020) (18)
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection (2021) (18)
Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment‐related anaemia: the need for predictors and indicators of effectiveness has not abated (2008) (18)
Applications of monoclonal antibodies for the treatment of hematological malignancies (2009) (18)
Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism. (2014) (18)
The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines. (2006) (18)
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. (2021) (17)
Inflammatory pseudotumor of the spleen: a case report and review of the literature (1999) (17)
Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature (2001) (17)
Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. (2006) (17)
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. (2012) (17)
The role of sclerostin/dickkopf‐1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross‐sectional study (2018) (17)
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy (2014) (17)
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America (2018) (17)
Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. (2014) (17)
Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. (2016) (17)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study (2013) (16)
Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study) (2016) (16)
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma (2016) (16)
Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. (2012) (16)
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases (2009) (16)
Red Cells with Paroxysmal Nocturnal Hemoglobinuria-phenotype in Patients with Acute Leukemia (2002) (16)
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. (2016) (16)
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma (2010) (16)
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine (2021) (16)
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma (2019) (16)
Leukemogenic Risk of Hydroxyurea Therapy as a Single Agent in Polycythemia Vera and Essential Thrombocythemia: N-and K-ras Mutations and Microsatellite Instability in Chromosomes 5 and 7 in 69 Patients (2002) (16)
Lenalidomide‐associated pneumonitis in patients with plasma cell dyscrasias (2011) (16)
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. (2015) (16)
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis (2020) (15)
Continuous Increase in Erythropoietic Activity despite the Improvement in Bone Mineral Density by Zoledronic Acid in Patients with Thalassemia Intermedia-Induced Osteoporosis (2008) (15)
The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon (2014) (15)
Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma (2020) (15)
Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? (2021) (15)
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment (2016) (15)
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates (2019) (15)
Correlation of Fc-γ RIIA polymorphisms with latent Epstein–Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas (2013) (15)
Successful Treatment of Extramedullary Plasmacytoma of the Carvenous Sinus Using a Combination of Intermediate Dose of Thalidomide and Dexamethasone (2006) (15)
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma (2019) (15)
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy (2022) (15)
Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background (2021) (15)
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. (2017) (15)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US (2021) (15)
The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension. (2019) (14)
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals (2021) (14)
Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment (2001) (14)
Detection of "PNH red cell" populations in hematological disorders using the Sephacryl Gel Test micro typing system. (1997) (14)
The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone (2009) (14)
Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia (2017) (14)
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece (2020) (14)
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide (2002) (14)
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients (2020) (14)
Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. (2017) (14)
BCMA in Multiple Myeloma—A Promising Key to Therapy (2021) (14)
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. (2018) (14)
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors (2021) (14)
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222 (2022) (14)
Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging (2015) (14)
Myelodysplastic features in patients with long‐term HIV infection and haemophilia (2001) (14)
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology (2021) (14)
Rituximab-based treatments in Waldenström's macroglobulinemia. (2009) (14)
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia (2010) (13)
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival (2018) (13)
Unusual Association between Increased Bone Resorption and Presence of Paroxysmal Nocturnal Hemoglobinuria Phenotype in Multiple Myeloma (2003) (13)
Current treatment options for myeloma (2005) (13)
Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy (2012) (13)
Reduced bone mineral density in adult patients with Langerhans cell histiocytosis (2012) (13)
Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment. (2008) (13)
Myelodysplastic features in patients with long-term HIV infection and haemophilia. (2001) (13)
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection (2021) (13)
Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid (2009) (13)
Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy (2019) (13)
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome (2020) (13)
Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance (2016) (12)
Lenalidomide: an update on evidence from clinical trials. (2010) (12)
Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group (2016) (12)
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. (2016) (12)
Prevention and Treatment of Myeloma Bone Disease (2012) (12)
Emerging treatment approaches for myeloma-related bone disease (2017) (12)
Distinct neutralization profile of spike variants by antibodies induced upon SARS‐CoV‐2 infection or vaccination (2021) (12)
Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice (2018) (12)
Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients (2013) (12)
Paget’s disease of bone: emphasis on treatment with zoledronic acid (2009) (12)
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care? (2019) (12)
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017. (2018) (12)
Effects of single‐agent bortezomib as post‐transplant consolidation therapy on multiple myeloma‐related bone disease: a randomized phase II study (2017) (12)
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment (2015) (12)
Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis (2014) (12)
Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide. (2004) (12)
Non-secretory myeloma: one, two, or more entities? (2013) (11)
Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice (2018) (11)
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) (11)
Incorporating novel agents in the treatment of myelodysplastic syndromes. (2010) (11)
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. (2011) (11)
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. (2021) (11)
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. (2019) (11)
Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making (2019) (11)
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma (2020) (11)
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome (2019) (11)
An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma (2017) (11)
Avascular Osteonecrosis of the Jaw as a Side Effect of Bisphosphonate Treatment (2010) (11)
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma (2018) (11)
Increased expression of platelet derived growth factor receptor β on trephine biopsies correlates with advanced myeloma. (2017) (11)
Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies (2015) (11)
Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma (2016) (11)
VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group. (2006) (11)
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients (2010) (11)
Variation of endothelium‐related hemostatic factors during sepsis (2018) (11)
Multiple Myeloma and Other Plasma Cell Neoplasms (2018) (11)
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. (2021) (11)
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response (2021) (10)
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients (2019) (10)
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS‐CoV‐2: Results of a prospective study in 150 health professionals in Greece (2022) (10)
The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis (2018) (10)
Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance (2020) (10)
Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age. (2004) (10)
Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response (2021) (10)
Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study (2018) (10)
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study (2021) (10)
Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting. (2020) (10)
Angiogenesis in Waldenström's macroglobulinemia. (2009) (10)
DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). (2020) (10)
A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis. (2009) (10)
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia (2017) (10)
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies (2021) (10)
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis. (2012) (10)
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO). (2018) (10)
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma (2019) (10)
Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. (2009) (10)
Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib (2010) (10)
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents (2020) (10)
"Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases (2017) (9)
Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study (2022) (9)
Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker (2022) (9)
A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma (2021) (9)
The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. (2011) (9)
Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19 (2021) (9)
Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics (2019) (9)
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination (2022) (9)
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy. (2007) (9)
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. (2019) (9)
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease. (2008) (9)
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM) (2016) (9)
High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. (2009) (9)
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. (2020) (9)
Increased expression of cyclin‐D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents (2012) (9)
Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group (2019) (9)
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients (2021) (9)
Cell‐free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations (2020) (9)
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent (2018) (9)
Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis? (2012) (9)
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients. (2009) (9)
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis (2021) (9)
The extended 4-year follow-up results of the ELOQUENT-2 trial (2019) (9)
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma (2019) (9)
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques (2021) (9)
Bortezomib in multiple myeloma (2008) (9)
Severe aplastic anaemia relapsing during a pregnancy; spontaneous remission following termination. (1998) (8)
Short progression‐free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent‐based therapy (2011) (8)
Antibody therapies for multiple myeloma (2020) (8)
Updates on thrombotic events associated with multiple myeloma (2019) (8)
Applications of monoclonal antibodies for the treatment of hematological malignancies. (2009) (8)
Autoimmune Hemolytic Anemia with Myelodysplastic Features Followed by Bilateral Adrenal Non-Hodgkin Lymphoma: A Case Report and Review of the Literature (2004) (8)
Bisphosphonate anticancer activity in multiple myeloma. (2012) (8)
Novel agents for the management of myelodysplastic syndromes. (2006) (8)
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome (2019) (8)
Prechemotherapy Serum Levels of CD105, Transforming Growth Factor &bgr;2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy (2009) (8)
How I treat elderly patients with plasma cell dyscrasias (2018) (8)
Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib (2020) (8)
Solitary bone plasmacytomas need to flow. (2014) (8)
Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients with Congenital Coagulation Disorders (2008) (8)
Management of multiple myeloma bone disease: impact of treatment on renal function (2018) (8)
Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma (2013) (8)
Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints (2021) (8)
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy (2022) (8)
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies (2022) (8)
Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers (2021) (8)
Is it possible to cure myeloma without allogeneic transplantation? (2016) (8)
Going the distance: Are we losing patients along the multiple myeloma treatment pathway? (2018) (8)
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. (2020) (8)
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection (2021) (8)
Controversies in the use of new bone‐modifying therapies in multiple myeloma (2020) (8)
Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review (2020) (8)
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome (2021) (8)
Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma (2019) (8)
Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity (2015) (8)
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (2019) (7)
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis (2021) (7)
Emerging drugs for Waldenström's macroglobulinemia (2011) (7)
How I Treat Relapsed Multiple Myeloma. (2022) (7)
Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity (2008) (7)
Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients (2015) (7)
Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. (2021) (7)
High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia (2010) (7)
Liver Transient Elastography (FibroScan) Correlates with Liver Iron Concentration and Reflects Liver Fibrosis In Patients with Sickle Cell Disease (2010) (7)
The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone. (2009) (7)
Genetic predisposition for the development of ONJ. (2008) (7)
Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy (2014) (7)
An update on the use of lenalidomide for the treatment of multiple myeloma (2015) (7)
Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis (2017) (7)
Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy (2019) (7)
Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury. (2012) (7)
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study (2019) (7)
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors (2021) (7)
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study (2018) (7)
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period (2020) (7)
Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network (2009) (7)
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group (2021) (7)
Evaluation of bone involvement in patients with Gaucher disease: a semi‐quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semi‐quantitative methods used so far (2015) (7)
Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 (2020) (7)
Haemophilia and low bone mass. Ok, but what about fracture risk? (2016) (7)
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection (2020) (7)
Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study. (2013) (7)
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma (2016) (7)
Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. (2020) (7)
Transplantation strategies for the management of patients with myelodysplastic syndromes. (2009) (7)
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? (2014) (7)
Association between anthropometric characteristics and bladder cancer risk: a systematic review and meta-analysis of longitudinal cohort studies (2020) (7)
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response (2002) (6)
Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses (2021) (6)
Serum homocysteine, folate and vitamin B12 in patients with Paget’s disease of bone: the effect of zoledronic acid (2010) (6)
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities. (2009) (6)
Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient (2013) (6)
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment (2020) (6)
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study (2021) (6)
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study (2010) (6)
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis (2019) (6)
Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries (2016) (6)
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy (2019) (6)
Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies (2021) (6)
Efficacy and safety of elotuzumab for the treatment of multiple myeloma (2017) (6)
The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients, (2011) (6)
Danazol Therapy for Thrombocytopenia in Patients with Myelodysplastic Syndromes (2002) (6)
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition (2022) (6)
Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. (2002) (6)
Proteasome inhibitor therapy for Waldenström's macroglobulinemia. (2013) (6)
Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome (2017) (6)
Serum Ferritin in Patients with Nonalcoholic Fatty Liver Disease: Evaluation of Ferritin to Adiponectin Ratio and Ferritin by Homeostatic Model of Assessment Insulin Resistance Product as Non-Invasive Markers (2012) (6)
Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. (2016) (6)
Hematology: First-line bortezomib benefits patients with multiple myeloma (2009) (6)
Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals (2022) (5)
Circulating periostin in patients with nonalcoholic fatty liver disease (2017) (5)
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C‐C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia (2018) (5)
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease (2021) (5)
1035TiPA multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO (2017) (5)
Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease (2012) (5)
Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization (2018) (5)
Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin (2021) (5)
Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study (2017) (5)
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients (2021) (5)
Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis (2010) (5)
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy (2020) (5)
Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study (2020) (5)
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. (2021) (5)
The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study (2010) (5)
Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis (2016) (5)
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2021) (5)
The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio. (2007) (5)
Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study (2018) (5)
Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes (2014) (5)
Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours (2006) (5)
A new pet for myeloma. (2009) (5)
Macrophage Inflammatory Protein‐1 alpha (MIP‐1α) is over‐expressed in a cohort of patients with myelodysplastic syndromes (2005) (4)
Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy (2021) (4)
Real World Treatment of Patients with Relapsed/Refractory Myeloma (2019) (4)
Antibodies to dickkopf-1 protein (2006) (4)
Prolonged Administration of Hydroxyurea Reduces Morbidity and Mortality in Adult Patients with Sickle-Cell Syndromes: Long-Term Experience of a Single Center. (2008) (4)
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. (2012) (4)
Decreased incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosis. (2013) (4)
Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia. (2008) (4)
TP53 mutations determined by targeted NGS in breast cancer: a case-control study (2021) (4)
Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG) (2008) (4)
Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. (2021) (4)
IMiDs for myeloma induced renal impairment (2018) (4)
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment (2018) (4)
Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group (2018) (4)
Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment (2013) (4)
Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients (2019) (4)
The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells (2022) (4)
Angiogenic Molecules and Inflammatory Cytokines in Patients with Thalassemia Major and Double Heterozygous HbS/Beta-Thalassemia; the impact of Deferasirox. (2009) (4)
Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group (2011) (4)
The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM). (2007) (4)
Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma (2010) (4)
Rare manifestations of extramedullary myeloma: testicular plasmacytomas (2018) (4)
Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response (2022) (4)
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group (2018) (4)
Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery—The Prospective Observational ROADMAP-Post COVID-19 Study (2022) (4)
Macrophage Inflammatory Protein-1 alpha (MIP-1alpha) is over-expressed in a cohort of patients with myelodysplastic syndromes. (2005) (4)
SERUM DIKKOPF-1 LEVELS IN POSTMENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS BEFORE AND AFTER TREATMENT WITH TERIPARATIDE (2009) (4)
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma (2017) (4)
Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma. (2007) (4)
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases (2018) (4)
Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. (2022) (4)
When to recommend a second autograft in patients with relapsed myeloma? (2017) (3)
S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY (2022) (3)
Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit (2021) (3)
Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients (2022) (3)
Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens (2010) (3)
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma (2021) (3)
Distinct Immunogenetic Signatures in IgA Versus IgG Multiple Myeloma (2016) (3)
The Spectrum of Ocular Manifestations in Patients with Waldenström’s Macroglobulinemia (2021) (3)
Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (2021) (3)
Bone disease in haemoglobin disorders (2013) (3)
Consumption of Fruits, Vegetables and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Cohort Studies (2021) (3)
Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors. (2008) (3)
A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study: MM‐230 (2018) (3)
Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells (2019) (3)
Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma. (2015) (3)
Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group (2011) (3)
Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density (2019) (3)
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial (2022) (3)
Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology (2019) (3)
Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone. (2007) (3)
Proposal for a novel prognostic index ( RANKL ) / osteoprotegerin ( OPG ) ratio predicts survival in multiple (2003) (3)
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study (2021) (3)
Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma. (2006) (3)
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls (2022) (3)
PCN117 Health Resource Utilisation (HRU) Associated with Skeletal-Related Events (SREs) in Patients with Bone Metastases (BMS): Results From a Retrospective, Multinational European Study (2011) (3)
The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents (2020) (3)
The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA) (2013) (3)
Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. (2010) (3)
Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL) (2008) (3)
Serological testing for SARS-CoV-2: Advancements and future challenges (2022) (3)
Fetal Erythropoiesis after Allogeneic Bone Marrow Transplantation Estimated by the Peripheral Blood Erythrocytes Containing Hemoglobin F (F-cells) (2001) (3)
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications (2021) (3)
Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients (2017) (3)
Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study (2022) (3)
Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers? (2020) (3)
Next Generation Flow (NGF) Cytometry for Minimal Residual Disease (MRD) Evaluation in Multiple Myeloma (MM) Patients with Sustained Complete Response (CR) after Frontline Therapy: Results of a Prospective Single-Center Analysis (2017) (3)
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. (2019) (3)
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met. (2008) (3)
Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment (2014) (3)
Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study (2015) (3)
Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin? (2021) (3)
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis. (2009) (3)
Kinetics of anti‐SARS‐CoV‐2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy (2021) (3)
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma (2021) (3)
Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens. (2007) (3)
Treatment with Deferasirox Effectively Decreases Iron Burden in Patients with Sickle Cell Disease and Thalassemia Intermedia. (2009) (3)
Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study (2020) (3)
Association of obesity and other anthropometric characteristics with bladder cancer risk: a systematic review and meta-analysis of longitudinal cohort studies. (2021) (3)
Less strength and more fractures for MGUS bones. (2014) (3)
tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature (2021) (3)
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies (2022) (3)
Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients (2014) (3)
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma (2016) (3)
Periostin and sclerostin levels in juvenile Paget's disease. (2017) (3)
Carfilzomib for treating myeloma (2016) (3)
Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma (2010) (3)
The Role of Angiopoietins System in Waldenstrom's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival (2012) (3)
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma (2022) (2)
Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents (2012) (2)
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study (2019) (2)
The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan (2015) (2)
Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple Myeloma (2017) (2)
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD” (2022) (2)
IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents (2013) (2)
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications (2022) (2)
Survivin messenger RNA levels in Epstein-Barr virus-positive patients with leukemic low-grade B-cell lymphomas expressing the latent membrane protein 1: evidence of apoptotic function? (2014) (2)
Continuous Improvement of Bone Mineral Density Two Years Post Zoledronic Acid Discontinuation in Patients with Thalassemia-Induced Osteoporosis: Long-Term Follow-Up of a Randomized, Placebo-Controlled Trial. (2007) (2)
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis (2020) (2)
Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease? (2011) (2)
The International Prognostic Scoring System for Waldestrom’s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens. (2007) (2)
Osteoporosis in thalassaemia (2018) (2)
PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US (2019) (2)
Reply to C.A. Hutchison et al (2011) (2)
Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease (2015) (2)
Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients (2018) (2)
Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study (2015) (2)
Bisphosphonate treatment for the management of osteoporosis in beta‐thalassaemia (2004) (2)
Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC). (2010) (2)
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis (2022) (2)
Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults (2022) (2)
Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma (2016) (2)
Other Complications of Multiple Myeloma (2018) (2)
Involvement of osteocytes in cancer bone niche (2015) (2)
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. (2022) (2)
Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy. (2019) (2)
Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel (2020) (2)
Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients (2013) (2)
Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens. (2007) (2)
Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. (2016) (2)
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis (2017) (2)
Increased Von Willebrand Factor and High Circulating Placental Growth Factor Correlate with Inflammation and Iron Overload in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia (2014) (2)
Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction (2013) (2)
Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study (2020) (2)
Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity (2022) (2)
A345 High Baseline NTX Predicts for Inferior Survival and Shorter Time to First SRE in Multiple Myeloma (2009) (2)
Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. (2017) (2)
Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome (2011) (2)
319 Response to treatment with erythropoietin in patients with MDS highly predicts low risk of evolution to AML and longer survival (2011) (2)
Increased RANKL and IL-6 levels might result in high bone turnover in a case of a CD34+/CD117+/myeloperoxidase(+dim) acute myeloid leukemia presenting with severe hypercalcemia and lumbar spine fractures. (2011) (2)
Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP (2013) (2)
Screening for Gaucher disease among patients with plasma cell dyscrasias (2019) (2)
Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers (2013) (2)
Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group (2020) (2)
Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study (2022) (2)
Advances in the treatment of multiple myeloma. (2011) (2)
PS1392 CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD (2019) (2)
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies (2022) (2)
Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom’s Macroglobulinemia (2013) (2)
Real-World Treatment of Patients With Relapsed/Refractory Myeloma. (2021) (2)
High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens (2012) (2)
A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients (2019) (2)
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL). (2017) (2)
Prognostication of the high-risk WM patient. (2011) (2)
1086 Biochemical markers of bone remodeling as predictors of skeletal morbidity and outcome in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid (2009) (2)
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials (2023) (2)
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. (2021) (2)
Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study (2019) (2)
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison (2020) (2)
No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience (2014) (2)
Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study (2018) (2)
Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia (2022) (2)
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study (2020) (2)
High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease (2012) (1)
Multiple Myeloma: Criteria for Diagnosis and Response to Therapy (2018) (1)
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS) (2019) (1)
Biology and management of myeloma-related bone disease (2014) (1)
Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies (2012) (1)
Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. (2022) (1)
The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis (2016) (1)
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma, (2011) (1)
The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma (2019) (1)
Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma. (2007) (1)
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe (2022) (1)
A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma. (2014) (1)
Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients (2012) (1)
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment (2022) (1)
Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis (2019) (1)
Disease and treatment parameters significantly affect skeletal complications and survival in metastatic breast cancer (2008) (1)
Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis (2022) (1)
Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor (2000) (1)
Bone marrow biopsy in low-risk MGUS patients reveals a novel MGUS-like Smoldering multiple myeloma risk group (2019) (1)
Have myeloma cells osteoclast-like activity? Implications into the pathogenesis of myeloma bone disease. (2008) (1)
Iron Overload of the Kidneys of Patients with Thalassemia and Sickle-Cell Disease: Final Results of a Prospective Study in 224 Patients Using Magnetic Resonance Imaging T2 and R2* Techniques (2015) (1)
Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease. (2010) (1)
First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL). (2009) (1)
Development and Validation of A Conceptual Model of Multiple Myeloma. (2015) (1)
Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum. (2011) (1)
XBB.1.5 neutralizing antibodies upon bivalent COVID‐19 vaccination are similar to XBB but lower than BQ.1.1 (2023) (1)
Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals (2022) (1)
COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus (2022) (1)
Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis (2018) (1)
The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis. (2008) (1)
67 Response to ESA treatment in patients with MDS: Determination of a predictive score, from a retrospective analysis of 669 patients (2011) (1)
Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group (2011) (1)
macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse (2013) (1)
Increased Expression of Cyclin-D1 on Trephine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents (2010) (1)
COVID-19 AND MYELOMA (2022) (1)
Protective Effects of Daratumumab on Carfilzomib-Related Cardiac Dysfunction in Patients with Relapsed Multiple Myeloma: Results from an Observational Study (2020) (1)
Oncology and public health (2012) (1)
Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study) (2019) (1)
Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms (2017) (1)
Evaluation of Experimental Retreatment and Prolonged Therapy with Subcutaneous (SC) Bortezomib in Patients (Pts) with Multiple Myeloma in First or Second Relapse, a Randomized, Controlled, Phase 3 Study (2016) (1)
Optimizing therapy in bortezomib-exposed patients with multiple myeloma (2018) (1)
Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices (2022) (1)
Cadherin‐11 (CDH11) expression in the peripheral blood of patients with active Multiple Myeloma (2017) (1)
Imatinib and chronic myeloid leukemia: close to the bone (2013) (1)
Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α (2020) (1)
Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo (2018) (1)
High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (2011) (1)
Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis. (2021) (1)
Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study (2021) (1)
Anti-Angiogenic Effect of Bortezomib in Multiple Myeloma Patients. (2004) (1)
Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma (2015) (1)
Incidence of Skeletal-Related Events at Diagnosis and at the Time of First Relapse in 463 Patients with Multiple Myeloma Who Received First Line Treatment in a Single Center (2019) (1)
Development of A Conceptual Model of Multiple Myeloma for Use In Economic Modelling: A Systematic Literature Review to Identify The Evidence Base. (2015) (1)
Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations (2011) (1)
Response of an oncology unit in the midst of the COVID-19 outbreak (2020) (1)
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19: The COMPASS-COVID-19 Prospective Observational Cohort Study (2020) (1)
Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study (2021) (1)
Deferasirox Reduces Serum TNF-α but Impairs Renal Function in Patients with Thalassemia Major after 12 Months of Therapy (2008) (1)
Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial. (2015) (1)
Pathophysiology and Management of Bone Metastases in Lung Cancer (2006) (1)
The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia (2015) (1)
Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone (2022) (1)
Understanding the molecular mosaic of cardiotoxicity of light chains in plasma cell dyscrasias and cardiac light chain amyloidosis with the use of patient derived full-length light chains (2022) (1)
Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial (2012) (1)
Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study (2020) (1)
The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19 (2022) (1)
Practical Considerations for Bone Health in Multiple Myeloma (2018) (1)
Frontline induction therapy for multiple myeloma (MM) in real-world clinical practice: Third interim analysis of the multinational, observational EMMOS study (NCT01241396) (2015) (1)
Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents (2013) (1)
Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study (2021) (1)
Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment (2020) (1)
Study of bone metabolism and angiogenesis in patients undergoing high‐dose chemotherapy/autologous hematopoietic stem cell transplantation (2018) (1)
No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years (2010) (1)
Pre-Treatment Status and Changes in Autoantibodies, Lymphocytic Populations, Cytokines and VEGF during Sunitinib Treatment of Metastatic Renal Cell Carcinoma (mRCC) (2014) (1)
OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study (2021) (1)
Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefits from zoledronic acid (2011) (1)
Lenalidomide Administration In Patients With POEMS Syndrome (2013) (1)
Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel (2022) (1)
Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis (2019) (1)
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction (2020) (1)
Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study. (2009) (1)
Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause (2019) (1)
Hodgkin's lymphoma. (2009) (1)
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2022) (1)
The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma. (2007) (1)
The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients. (2009) (1)
Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma (2014) (1)
Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment. (2009) (1)
The Serum Levels of N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) Is a Strong Indicator of Pulmonary Hypertension in Patients with Sickle Cell/Beta Thalassemia. (2006) (1)
Integrin expression in correlation to clinicopathological features and prognosis of prostate cancer: A systematic review and meta-analysis. (2021) (1)
T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study (2020) (1)
A Prospective Phase II Study on The Use Of Convalescent Plasma Monotherapy For The Treatment of Severe Covid-19 Disease: A Preliminary Report. (2020) (1)
Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality (2021) (1)
Mineralocorticoid receptor signaling is implicated in carfilzomib-induced increase in blood pressure (2021) (1)
Correlation of Erythropoietin Stimulating Agents (ESAs) with the Post-Therapy Micro-Vessel Density (MVD) in Newly Diagnosed Myeloma Patients: a Possible Mechanism of ESAs Association with Reduced Survival Rates. (2009) (1)
Systemic IL-15, IFN-γ and IP-10/CXCL10 Signature Associated With Effective Immune Response in BNT162b2 mRNA Vaccine Recipients (2021) (1)
Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important (2016) (1)
Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes (2021) (1)
33P Immune checkpoint inhibitor-induced cardiotoxicity is driven through inflammation, autophagy and stress (2022) (1)
Flow-Mediated Dilatation (FMD) and Aortic Blood Pressure May Predict Cardiovascular Adverse Events During Carfilzomib Therapy: A Prospective Study in Relapsed/Refractory Multiple Myeloma Patients (2019) (1)
Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients (2019) (1)
Real-World Use of Carfilzomib Therapy Among Patients With Existing Cardiovascular Medical History: An Analysis of a Prospective Observational Study (2019) (1)
Increased Bone Resorption Is Implicated in the Pathogenesis of Bone Loss in Hemophilia Patients: Correlations with Severity of Hemophilic Arthropathy and HIV Infection. (2007) (1)
Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice (2015) (1)
Real-World Evidence of the Use of Carfilzomib and Dexamethasone According to Age Subgroup: An Interim Analysis From a Prospective Observational Study (2019) (1)
PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMA (2018) (1)
Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients (2022) (1)
Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study (2018) (1)
Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption (2011) (1)
Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients (2014) (1)
Dickkopf-1 and sclerostin in different phases of multiple myeloma; The effect of lenalidomide and dexamethasone treatment with or without bortezomib (2011) (1)
A Revised Staging System for Waldenström's Macroglobulinemia (2017) (1)
The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation (2012) (1)
Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group (2006) (1)
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents (2022) (1)
Outcome of treatment for first versus later relapse in multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study (2015) (1)
P-151: Incidence of adverse events in patients with Multiple Myeloma who continued with Denosumab after receiving Denosumab or Zoledronic acid: an open-label extension study (2021) (1)
Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma (2010) (1)
RED CELLS, IRON, AND ERYTHROPOIESIS Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-de ﬁ cient cells (2014) (1)
MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody (2022) (1)
Primary Treatment of Light Chain (AL) Amyloidosis With Bortezomib, Lenalidomide and Dexamethasone (VRD) or with Bortezomib, Cyclophosphamide and Dexamethasone (VCD/CyBorD): efficacy and toxicity (2018) (1)
Indirubins: A Potential Therapeutic Target in Multiple Myeloma (2016) (1)
Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period (2018) (1)
Reply to D.L. Cooper. (2015) (0)
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy (2019) (0)
PF616 REAL-WORLD USE OF THE TRIPLET REGIMEN CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A SUB-GROUP INTERIM ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY (2019) (0)
Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome. (2007) (0)
P1507: CLINICAL PROFILE OF COVID-19 INFECTION AND IMMUNE RESPONSE AFTER 3AND6 MONTH VACCINATION AGAINST SARS-COV-2 IN ADULT PATIENTS WITH TRANSFUSION-DEPENDENT THALASSAEMIA-THE EXPERIENCE OF A GREEK CENTER (2022) (0)
A-177 Evaluation of Multiplex Ligation-Dependent Probe Amplification as a method for detection of IKZF 1 ( Ikaros ) deletions in B-cell precursor acute lymphoblastic leukemia (2015) (0)
The Management and Costs of Multiple Myeloma in Greece: Mapping the Local Treatment Pathway and Associated Resource Use (2016) (0)
Dynamic contrast-enhanced MRI parameters correlate with angiopoietin-1/angiopoietin-2 ratio and high-risk features in patients with multiple myeloma (2015) (0)
Iconographies supplémentaires de l'article : Zoledronic acid for all patients with newly diagnosed multiple myeloma? (2011) (0)
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly diagnosed chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer-associated Thrombosis. The Observational ROADMAP-CAT-MM Study (2018) (0)
Identi ﬁ cation of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP (2021) (0)
B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA (2022) (0)
Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival (2016) (0)
Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry (2018) (0)
Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications. (2023) (0)
Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent? (2022) (0)
Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Diagnostic and Response Criteria (2023) (0)
P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination (2021) (0)
Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation (14;16): An Ultra-High-Risk Group of Myeloma Patients (2017) (0)
Important Links Between Fat Derived Proteins and Bone Remodeling Factors in Lean and Obese Girls (2014) (0)
Prognostic Contribution of the New Immunoglobulin (Ig) Biomarkers (Freelite™ and Hevylite™) in Waldenstrom's Macroglobulinemia (WM) (2012) (0)
Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosis. (2022) (0)
Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center (2022) (0)
Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System? (2013) (0)
Reply to ‘Proteasome inhibition therapies in childhood cancer’ by Zaman et al. (2008) (0)
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop (2019) (0)
Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination (2021) (0)
Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis (2020) (0)
Persisting Endothelial Cell Activation and Hypercoagulability after Recovering from COVID-19: The Roadmap-Post COVID-19 Study (2022) (0)
Prognostic and predictive significance of VEGF and TNFα levels in ascites of patients with epithelial ovarian cancer. Correlation with lymphocytes subpopulations (2016) (0)
P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents (2022) (0)
Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor (2014) (0)
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study (2023) (0)
Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic (2021) (0)
Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients (2008) (0)
Two-drug Combinations in the Treatment of Multiple Myeloma (2015) (0)
High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome. (2007) (0)
MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF) (2020) (0)
Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging (2020) (0)
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. (2023) (0)
Molecular Analyses Of The Effects Induced By Orally Administered Bortezomib In Drosophila Flies: A Novel In Vivo Experimental Platform To Screen For The Tissue- and Age-Dependent Effects Of Proteasome Inhibitors (2013) (0)
Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19) (2022) (0)
Evidence-Based Focused Optimal use of bisphosphonates in patients with multiple myeloma (2013) (0)
A014 High Serum TIMP-1 Correlates with Advanced Myeloma and Poor Survival (2009) (0)
B157 Immunoglobulin Genes in IgG Versus IgA Multiple Myeloma (2009) (0)
Dickkopf-1:asuitabletargetfor themanagementofmyeloma bonedisease (2009) (0)
Contents Vol. 107, 2002 (2002) (0)
Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years (2010) (0)
Systemic Mastocytosis as a Cause of Severe Osteoporosis in a Young Woman (2010) (0)
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma (2022) (0)
Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens (2016) (0)
Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy (2011) (0)
Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf). (2021) (0)
P4787Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy (2018) (0)
Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients (2022) (0)
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice (2021) (0)
Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study (2019) (0)
type and Waldenström macroglobulinemia for monoclonal gammopathy of undetermined significance of the IgM Hyperphosphorylated paratarg-7: a new molecularly defined risk factor (2013) (0)
Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group (2016) (0)
Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era (2022) (0)
Poster: MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy (2022) (0)
Deficiency in DNA repair pathways of peripheral blood mononuclear cells correlates with better clinical outcome of myeloma patients (2015) (0)
University of Southern Denmark Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
AB0047 Cd55 Red-Cell Expression in Systemic Autoimmune Disease Reflects Its Impact on Erythropoiesis through Immune-Mediated Bone Marrow Insufficiency (2014) (0)
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer‐Associated Thrombosis. The Observational ROADMAT‐CAT‐MM Study: MM‐021 (2018) (0)
Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study (2017) (0)
Deficient double strand breaks repair of bone marrow plasma cells correlates with better clinical outcome of multiple myeloma patients (2014) (0)
Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease (2017) (0)
Osteoimmunology and Cancer - Clinical Implications (2011) (0)
Minimal residual disease detection in multiple myeloma: methods and prognostic significance (2020) (0)
Biochemical Markers of Bone Remodeling in Multiple Myeloma (2010) (0)
Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens. (2009) (0)
Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis (2011) (0)
PP80 - Differential regulation of the proteasome and of antioxidant responses during aging in the somatic tissues and the gonads of Drosophila (2013) (0)
P-220: Use of Carfilzomib regimens in patients with Multiple Myeloma refractory to CD38 antibodies: a subgroup analysis from a prospective observational study (2021) (0)
Evidence-Based Focused Review Optimal use of bisphosphonates in patients with multiple myeloma (2013) (0)
Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy (2021) (0)
Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients ≤65 Years of Age Compared to Patients >65 Years (2012) (0)
Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review (2022) (0)
Effects of single-agent bortezomib (btz) as post-transplant consolidation on multiple myeloma (MM)-related bone disease: first results from a multicenter, randomized phase 2 study (2014) (0)
Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study (2020) (0)
Increased Expression of the PRV-1 Gene in Thalassemia Reflects the Rate of the Underlying Erythropoietic Activity. (2005) (0)
High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens (2011) (0)
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival (2018) (0)
MM-039: Natural History of Skeletal-Related Events Among 620 Patients with Multiple Myeloma Who Received First- and Second-Line Therapy with Novel Agents: A Single-Center Analysis (2020) (0)
Global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients: the Insight-MM Study (2016) (0)
Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients (2022) (0)
The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met) (2018) (0)
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma (2018) (0)
Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents (2014) (0)
Sclerostin Remains Elevated Even in the Plateau Phase of Myeloma Patients: Implications into the Pathogenesis of Osteoblast Dysfunction of Multiple Myeloma (2015) (0)
Replacement Therapy with Imiglucerase Improves Magnetic Resonance Imaging (MRI) Abnormalities in Almost Half Patients with Non-Neuronopathic Form of Gaucher Disease After Twelve Months of Therapy: Results of a Semi-Quantitative MRI Method. (2012) (0)
Bone targeted therapy for Myeloma: future perspectives (2011) (0)
Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study (2016) (0)
Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma (2010) (0)
1369P RISK OF MAJOR BLEEDING IN CANCER PATIENTS RECEIVING CHEMOTHERAPY (2012) (0)
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma. (2009) (0)
P-051: Sustained bone marrow and imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study (2022) (0)
Accumulation of Endogenous DNA Damage Sustain Malignant Progression and Increase Therapy Resistance in Multiple Myeloma (2019) (0)
Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies (2022) (0)
Al amyloidosis with cardiac involvement: cardiotoxicity of aggregation prone peptides deriving from variable domains of immunoglobulin light chains (2020) (0)
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group (2022) (0)
The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma (2022) (0)
P-025: Investigating the effect of irreversible proteasome inhibitor carfilzomib in in vivo models of cardiometabolic syndrome and early stage HFrEFP: prophylactic role of metformin (2022) (0)
An in vitro and in vivo approach to decipher immune checkpoint inhibitors cardiotoxicity. Implications of endoplasmic reticulum stress, inflammation and autophagy (2022) (0)
Zoledronic Acid Is an Effective Treatment for Osteoporosis in Patients with Thalassemia Major: Results of a Randomized, Placebo-Controlled, Trial. (2005) (0)
Corrigendum to “Bortezomib upregulates the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease” [Leukemia Res. 34 (6) (2010) 700–701] (2011) (0)
Screening for Gaucher disease in patients with plasma cell dyscrasias (2019) (0)
Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study (2020) (0)
An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity (2022) (0)
P-36 Trisomy 8 alone in myelodysplasticsyndromes: Recognition of the common clinico-hematologic features from 109 patients (2005) (0)
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients (2021) (0)
Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants (2022) (0)
Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study) (2019) (0)
P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY (2022) (0)
Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study (2022) (0)
Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis (2015) (0)
Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data. (2005) (0)
Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd (2018) (0)
Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus (2012) (0)
P-209: High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma (2021) (0)
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis (2023) (0)
Investigation of the cardiotoxicity of full-length light chains derived from patients with cardiac light chain amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance (2022) (0)
Emerging Data on Management and Imaging of Myeloma Bone Disease (2018) (0)
Investigating the impact of aging and hyperlipidaemia on metformin cardioprotection against carfilzomib-induced cardiotoxicity in vivo (2020) (0)
RANKLinhibitionforthe managementofpatientswith benignmetabolicbonedisorders (2009) (0)
Osteocytes and bone tumor niche (2022) (0)
BONE DISEASE (2022) (0)
The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma (2022) (0)
High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern (2015) (0)
Low Circulating Levels of DKK-1 Protein in Obese Children Indicate Suppression of Canonical Wnt Signaling (2014) (0)
How I use Bone Support (2015) (0)
A novel microrna signature with clinical significance in multiple myeloma (2020) (0)
Zoledronic Acid Increases Bone Mineral Density in Patients with Thalassemia Intermedia-Induced Osteoporosis Regardless of the Incessant Bone Marrow Expansion. (2007) (0)
PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECE (2018) (0)
Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival (2011) (0)
Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma (2019) (0)
High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease (2014) (0)
Author's reply: To PMID 23705905. (2014) (0)
The effect of zoledronic acid on serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone (2010) (0)
The Compass-COVID19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19 (2021) (0)
P22: A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS OF THE ‘OL-ORAL’ STUDY (2022) (0)
Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece (2016) (0)
Derivation of Prediction Model for Treatment Failure Risk in Multiple Myeloma Patients Based on Biomarkers of Hypercoagulability. The Prospective Observational ROADMAP-MM-CAT Study (2019) (0)
Circulating Activin-A Is Elevated in Patients with Thalassemia Major and Double Heterozygous Sickle-Cell/Beta-Thalassemia and Correlates with Markers of Hemolysis and Bone Mineral Density (2012) (0)
Retrospective evaluation of the risk profile in chronic myelogenous leukemia (CML) according to a new prognostic scoring system (1999) (0)
Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma (2013) (0)
MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant (2022) (0)
What's new in bone research--anabolics, tissue repair, therapeutic strategies and more. (2006) (0)
Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients (2017) (0)
Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment. (2005) (0)
MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (2022) (0)
The role of ibrutinib in Waldenström macroglobulinemia (2018) (0)
Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity (2019) (0)
Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187) (2017) (0)
Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients. (2007) (0)
RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study (2017) (0)
Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach (2020) (0)
PS1393 PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD) (2019) (0)
22 Osteoimmunology and Cancer-Clinical Implications (2017) (0)
Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment (2019) (0)
Dignity therapy for patients who are terminally ill (2011) (0)
Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma (2011) (0)
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High‐risk Population: MM‐257 (2018) (0)
The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients. (2007) (0)
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management (2023) (0)
Hodgkin's lymphoma. (2006) (0)
1553TiPCOMPARISON OF DENOSUMAB VS ZOLEDRONIC ACID FOR TREATMENT OF BONE DISEASE IN ADULTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A RANDOMIZED, DOUBLE-BLIND, MULTINATIONAL PHASE 3 TRIAL. (2014) (0)
Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (2022) (0)
Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy (2013) (0)
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome (2021) (0)
IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure (2020) (0)
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group (2018) (0)
CONTINUING MEDICAL EDUCATION ΣYNEXIZOMENH IATPIKH EKΠAIΔEYΣH (2010) (0)
Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenstrom’s Macroglobulinemia: Implications into the Biology of the Disease (2008) (0)
Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events (2018) (0)
Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine (2021) (0)
Prognostic Significance of Circulating Plasma Cells Detected By Next Generation Flow Cytometry in Light (AL) Chain Amyloidosis (2022) (0)
Therapy of Myeloma Bone Disease (2021) (0)
Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens (2013) (0)
Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years (2013) (0)
Syddansk Universitet Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
PS1378 AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS (2019) (0)
Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy (2019) (0)
MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy. (2022) (0)
Recent therapeutic approaches in myeloma (2022) (0)
Dysfunction of Toll-Like Receptor-2, −4, and −6: Is There a Role in the Pathogenesis of Immunodeficiency in Multiple Myeloma?. (2006) (0)
Multiple Myeloma: How to Use Modern Imaging in Every Day Clinical Practice? (2018) (0)
Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents (2016) (0)
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events (2017) (0)
Blood transcriptomes of anti-SARS-CoV2 antibody positive healthy individuals with prior asymptomatic versus clinical infection (2021) (0)
B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (2022) (0)
Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death (2016) (0)
Characterization and clinical implications of peripheral arterial involvement in transthyretin cardiac amyloidosis cardiomyopathy (2020) (0)
Reply ‐ Is ibandronate effective in multiple myeloma? (2003) (0)
Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study (2022) (0)
Importance of minimal disease detection in multiple myeloma (2019) (0)
Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis. (2023) (0)
P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study (2022) (0)
Multiple Myeloma Bone Disease (2019) (0)
Obesity and multiple myeloma: emerging mechanisms and perspectives. (2023) (0)
Long Term Treatment with Hydroxyurea Does Not Prevent Development of Renal Dysfunction and Osteodystrophy in Patients with Sickle Cell Disease. (2004) (0)
A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy (2019) (0)
New Insights in Waldenström’s Macroglobulinemia (2012) (0)
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays (2021) (0)
Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study (2019) (0)
Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma (2012) (0)
Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom’s Macroglobulinemia and Correlates with the Severity of Disease. (2005) (0)
MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma (2021) (0)
Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma, (2011) (0)
Peripheral vascular involvement in transthyretin cardiac amyloidosis. A comparative analysis with AL amyloidosis (2021) (0)
Osteoporosis in Sickle Cell/β-Thalassemia Is Primarily Caused by an Imbalance at the RANKL/OPG Pathway. (2005) (0)
Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma (2011) (0)
Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease (2009) (0)
Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients (2021) (0)
Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy. (2015) (0)
Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan (2016) (0)
Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group (2018) (0)
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. (2021) (0)
High dose short term glucocorticoid (gc) treatment seems to have no long term negative effect on bone mineral density (bmd) of newly diagnosed multiple sclerosis (ms) patients (2021) (0)
SP-030 OPTIMIZING TREATMENT OF MULTIPLE MYELOMA COMPLICATIONS (2014) (0)
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). (2023) (0)
Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma. (2006) (0)
Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon? (2013) (0)
Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations (2014) (0)
High-Dose Intravenous Steroid Treatment Seems to Have No Long-Term Negative Effect on Bone Mineral Density of Young and Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study (2023) (0)
P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP (2022) (0)
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. (2022) (0)
Pathogenesis of bone disease in multiple myeloma: from bench to bedside (2018) (0)
Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy (2019) (0)
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life (2021) (0)
MM-252: Aberrant Plasma Cells in the Apheresis Product as a Prognostic Factor for Minimal Residual Disease Negativity After Transplant in Newly Diagnosed Myeloma Patients (2020) (0)
Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone (2017) (0)
The letter by Cooper 1 regarding our article on the role of (2015) (0)
Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy (2022) (0)
A425 EGFR Based on Cystatin-C, Creatinine, and Age Is Independently Associated with Survival in Myeloma (2009) (0)
Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece (2019) (0)
Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease (2011) (0)
Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response (2017) (0)
PS1394 FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (2019) (0)
Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide (2014) (0)
Phosphate levels inversely correlate with aortic stiffness in patients with primary hyperparathyroidism (2011) (0)
Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents (2014) (0)
PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB‐CHOP (RCHOP) ± RADIOTHERAPY (RT) (2019) (0)
A013 Immunoexpression of MIP-1alpha on Marrow Biopsies Correlates with the Extent of Myeloma Bone Disease (2009) (0)
Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR in patients with IgM-Monoclonal gammopathies. (2023) (0)
Zoledronic acid for all patients with newly diagnosed multiple myeloma? (2011) (0)
Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis (2014) (0)
MM-103: Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf) (2021) (0)
Sustained vasodilation after cold pressor test is an independent predictor of poor survival in primary AL amyloidosis (2022) (0)
Multiple myeloma (MM) vaccination (influenza, FV and pneumococcal, PV) rates worldwide and impact on infection, hospitalization, and death. (2020) (0)
Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy (2010) (0)
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories (2023) (0)
Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System (2011) (0)
Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis (2017) (0)
Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents. (2009) (0)
The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma (2014) (0)
Subject Index Vol. 107, 2002 (2002) (0)
Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM): Results from a randomized, open-label, multicenter, parallel-group phase 2 study (2015) (0)
Outcome of first salvage therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, observational, non-interventional EMMOS study (2015) (0)
Recent Advances In The Treatment Of Multiple Myeloma: Proceedings From a Post-ASCO Roundtable (2011) (0)
Real-World data for the Treatment of Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone in 2nd Line (Legend Study): The Prognostic Significance of Biochemical Versus Clinical Relapse (2017) (0)
High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features. (2007) (0)
Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study (2020) (0)
Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3, (2011) (0)
Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival (2017) (0)
The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma. (2007) (0)
Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications (2015) (0)
B-221 Circulating Dickkopf-1 Protein Levels in Normal-Weight and Obese Children : Evidence of Involvement of Canonical Wnt Signaling (2016) (0)
PF601 EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY (2019) (0)
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. (2022) (0)
P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin (2021) (0)
Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass (2019) (0)
The effect of VEGF on T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. (2011) (0)
Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles (2015) (0)
Global deterioration of cardiovascular mechanics by carfilzomib treatment is associated with proteasome activity in patients with relapsed multiple myeloma (2021) (0)
Elucidating the cardiac outcomes of irreversible proteasome inhibitor Carfilzomib in in vivo models of HFpEF and HFrEF. Preventive role of Metformin (2022) (0)
A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma. (2009) (0)
P-83 Expression of MIP-1α protein in 65 patients with myelodysplastic syndrome (MDS). A study of the Greek MDS study group (2005) (0)
Increased Osteoprotegerin Levels in Response to Increased Bone Resorption in AL Amyloidosis: Comparisons with Bone Remodeling of Multiple Myeloma. (2007) (0)
Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival. (2007) (0)
Patients with autoimmune thyroiditis present similar immunological response to COVID-19 BNT162b2 mRNA vaccine with healthy subjects, but vaccination may affect thyroid function (2022) (0)
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (0)
P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma (2021) (0)
Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes (2022) (0)
Time to Improve Bortezomib and Lenalidomide Lines of Therapy (2017) (0)
Novel treatments of multiple myeloma (2005) (0)
P1017 : Circulating sclerostin and DICKKOPF-1 in patients with Nonalcoholic Fatty Liver Disease (2015) (0)
P-249: Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis (2022) (0)
Increased Plasma Levels of NGAL and IL-18 Correlate with Reduced GFR Providing Two Novel Biomarkers for Kidney Injury Assessment: Evidence of Early Tubuloglomerular Defect in Patients with HbS/b-Thalassemia (2008) (0)
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19 (2020) (0)
Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans (2015) (0)
COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns (2022) (0)
Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trephine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma (2008) (0)
The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors (2015) (0)
A136 Len/Dex ± Bortezomib for Advanced Myeloma According to Prior Neuropathy: The Impact of Cytogenetics (2009) (0)
Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study (2021) (0)
Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy (2019) (0)
Molecular Mechanisms in Proteasome Inhibitor Induced Cardiotoxicty: Focus on Carfilzomib (2019) (0)
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis (2018) (0)
Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma (2010) (0)
Thrombophilic factors in patients with Syndrome X. (2000) (0)
Intravenous pamidronate for myeloma bone disease: can the dose be lowered? (2010) (0)
The Effect of Novel Anti-myeloma Agents on Bone Metabolism (2013) (0)
Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. (2016) (0)
miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma (2023) (0)
Management of Early Relapse, How to Navigate the Choices (2017) (0)
Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib (2014) (0)
A Study of the Expression of the LMP1 Oncoprotein in Low-Grade B Cell Lymphomas and Correlation with the Levels of Oxidative Stress (2012) (0)
Atlas of Hematology (2006) (0)
Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism and Hydroxyurea Treatment (2019) (0)
Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients (2011) (0)
P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? (2022) (0)
Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients (2021) (0)
Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells (2020) (0)
A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias (2020) (0)
P-268: INSURE: a global pooled analysis of patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with ixazomib-lenalidomidedexamethasone (IRd) in routine clinical practice (2022) (0)
Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology (2011) (0)
In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study (2018) (0)
Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study (2021) (0)
Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. (2012) (0)
Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation. (2009) (0)
and low-dose dexamethasone (RdC) in AL amyloidosis A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide (2012) (0)
Transfusion and Apheresis Science (2016) (0)
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study (2018) (0)
Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis (2008) (0)
Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study (2020) (0)
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study (2018) (0)
Health Resource Utilisation (HRU) in Europe Associated with Skeletal-Related Events (SRES): Results from a Retrospective Study (2012) (0)
Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Evangelos Terpos?

Evangelos Terpos is affiliated with the following schools:

Imperial College London
Stanford University
National and Kapodistrian University of Athens
University of Turin
University of Salamanca

Evangelos Terpos's Academic­Influence.com Rankings

Why Is Evangelos Terpos Influential?

Evangelos Terpos's Published Works

Published Works

What Schools Are Affiliated With Evangelos Terpos?

Evangelos Terpos's AcademicInfluence.com Rankings